Radiation Therapy: Fractionation, Image-Guidance, and Special Services

Policy Number: CS179.A
Effective Date: October 1, 2021

This Medical Policy only applies to the states of California, Florida, Maryland, Ohio, Rhode Island, Washington and Wisconsin.

Coverage Rationale

Radiation Therapy Fractionation

**Bone Metastases**

When providing external beam radiation therapy for the treatment of a bone metastasis the following are medically necessary:

- Single fraction of radiation therapy
- Delivery of up to 10 fractions when any of the following criteria are met:
  - Treatment of a weight bearing bone such as femur; or
  - Treating a bone that has previously undergone surgical stabilization; or
  - Treatment of spinal cord compression
- Delivery of greater than 10 fractions is medically necessary for the following:
  - Treatment of a site that has previously received radiation therapy

**Breast Adenocarcinoma**

When providing external beam radiation therapy for breast adenocarcinoma the following are medically necessary:

- Delivery of up to 21 fractions (inclusive of a boost to the tumor bed)
- Delivery of up to 33 fractions (inclusive of a boost to the tumor bed) is medically necessary when any of the following criteria are met:
  - Treatment of supraclavicular and/or internal mammary lymph nodes; or
  - Post-mastectomy radiation therapy; or

Related Community Plan Policies
- Intensity-Modulated Radiation Therapy
- Proton Beam Radiation Therapy
- Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery

Commercial Policy
- Radiation Therapy: Fractionation, Image-Guidance, and Special Services

Medicare Advantage Coverage Summary
- Radiologic Therapeutic Procedures
Individual has received previous thoracic radiation therapy
Individual has a connective tissue disorder such as lupus or scleroderma

When providing external beam radiation therapy for breast cancer, delivery of greater than 33 fractions (inclusive of a boost to the tumor bed) is not medically necessary.

**Locally Advanced Non-Small Cell Lung Cancer**
When providing external beam radiation therapy, with or without chemotherapy, for locally advanced non-small cell lung cancer, the following is medical necessary:
- Delivery of up to 30 fractions

When providing external beam radiation therapy, with or without chemotherapy, for locally advanced non-small cell lung cancer, delivery of greater than 30 fractions is not medically necessary.

**Prostate Adenocarcinoma**
When providing external beam radiation therapy for prostate adenocarcinoma the following are medically necessary:
- Delivery of up to 20 fractions for definitive treatment in an individual with limited metastatic disease
- Delivery of up to 28 fractions for localized prostate cancer
- Delivery of up to 45 fractions for localized prostate cancer when any of the following criteria are met:
  - Individual with high risk prostate cancer is undergoing radiation treatment to pelvic lymph nodes; or
  - Radiation therapy is delivered post-prostatectomy; or
  - External beam radiation therapy is being delivered in combination with brachytherapy; or
  - Individual has a history of inflammatory bowel disease such as ulcerative colitis or Crohn’s disease; or
  - Individual has received previous pelvic radiation therapy

When providing external beam radiation therapy for localized prostate cancer, delivery greater than 45 fractions is not medically necessary.

**Image-Guided Radiation Therapy (IGRT)**
Image guidance for radiation therapy is medically necessary under any of the following circumstances:
- When used with intensity modulated radiation therapy (IMRT); or
- When used with proton beam radiation therapy (PBRT); or
- For left sided breast cancer with the use of
  - Deep inspiration breath hold (DIBH) technique; or
  - Prone technique
- When the target has received prior radiation therapy or abuts previously irradiated area; or
- When implanted fiducial markers are being used for target localization; or
- During definitive treatment with radiation therapy using 3D-CRT for the following:
  - Central nervous system tumors
  - Primary head and neck cancer
  - Esophageal cancer
  - Mediastinal tumors
  - Prostate cancer
- Patients who are severely obese (BMI ≥ 35) and are being treated for abdominal and pelvic tumors
- Tumors with significant respiratory motion and motion assessment and management techniques are being utilized (e.g., 4D CT scan)

When the above criteria are not met, IGRT is not medically necessary including but not limited to any of the following circumstances:
- Brachytherapy
- Stereotactic body radiation therapy (SBRT)*
- Stereotactic radiosurgery (SRS)*
- Superficial treatment of skin cancer including superficial radiation therapy or electronic brachytherapy
- To align bony landmarks without implanted fiducials
Special Services

Special services include the need for special dosimetry, special medical physics consultation, and special treatment procedure. Refer to the Coding Clarification.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

Coding Clarification:

- Special dosimetry CPT code 77331 should be used to document the measurement of radiation dose using special radiation equipment such as thermoluminescent dosimeters (TLD), solid state diode probes, or special dosimetry probes. When special dosimetry is requested, the usual frequency will vary from one to six measurements. Any additional request will be evaluated on a case-by-case basis. IMRT planning (77301) includes special dosimetry (ASTRO 2020).

- Special medical radiation physics consultation CPT code 77370 should be reported once under the following circumstances: brachytherapy, stereotactic radiosurgery or stereotactic body radiation therapy, use of radioisotopes, patient has an implanted pacemaker or defibrillator device, reconstruction of previous radiation therapy plan, pregnant patient undergoing radiation therapy or fusion of three-dimensional image sets such as PET scan or MRI scan. IMRT planning (77301) includes fusion of three-dimensional image sets such as PET scan or MRI scan. (ASTRO 2020, CMS 2015).

- Special treatment procedure CPT code 77470 should be reported once under the following circumstances: brachytherapy, concurrent use of intravenous chemotherapy (except Herceptin use in breast cancer), reconstruction and analysis of previous radiation therapy plan, hyperthermia, total and hemi-body irradiation, per oral or endocavitary irradiation, and pediatric patient requiring anesthesia (ASTRO 2020).

- Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services CPT code 77399 should only be reported if no other code adequately describes the procedure or service in question (ASTRO 2020).

* IGRT cannot be reported separately with SBRT or SRS (ASTRO 2020).

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77014</td>
<td>Computed tomography guidance for placement of radiation therapy fields</td>
</tr>
<tr>
<td>77331</td>
<td>Special dosimetry (e.g., TLD, microdosimetry) (specify), only when prescribed by the treating physician</td>
</tr>
<tr>
<td>77370</td>
<td>Special medical radiation physics consultation</td>
</tr>
<tr>
<td>77385</td>
<td>Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple</td>
</tr>
<tr>
<td>77386</td>
<td>Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex</td>
</tr>
<tr>
<td>77387</td>
<td>Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed</td>
</tr>
<tr>
<td>77399</td>
<td>Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services</td>
</tr>
<tr>
<td>77401</td>
<td>Radiation treatment delivery, superficial and/or ortho voltage, per day</td>
</tr>
<tr>
<td>77402</td>
<td>Radiation treatment delivery, =&gt; 1 MeV; simple</td>
</tr>
</tbody>
</table>
### CPT Code

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77407</td>
<td>Radiation treatment delivery, =&gt; 1 MeV; intermediate</td>
</tr>
<tr>
<td>77412</td>
<td>Radiation treatment delivery, =&gt; 1 MeV; complex</td>
</tr>
<tr>
<td>77470</td>
<td>Special treatment procedure (e.g., total body irradiation, hemibody radiation, per oral or endocavitary irradiation)</td>
</tr>
<tr>
<td>77520</td>
<td>Proton treatment delivery; simple, without compensation</td>
</tr>
<tr>
<td>77522</td>
<td>Proton treatment delivery; simple, with compensation</td>
</tr>
<tr>
<td>77523</td>
<td>Proton treatment delivery; intermediate</td>
</tr>
<tr>
<td>77525</td>
<td>Proton treatment delivery; complex</td>
</tr>
</tbody>
</table>

_CPT® is a registered trademark of the American Medical Association_

---

### HCPCS Code

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G6001</td>
<td>Ultrasonic guidance for placement of radiation therapy fields</td>
</tr>
<tr>
<td>G6002</td>
<td>Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy</td>
</tr>
<tr>
<td>G6003</td>
<td>Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: up to 5 mev</td>
</tr>
<tr>
<td>G6004</td>
<td>Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 6-10 mev</td>
</tr>
<tr>
<td>G6005</td>
<td>Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 11-19 mev</td>
</tr>
<tr>
<td>G6006</td>
<td>Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 20 mev or greater</td>
</tr>
<tr>
<td>G6007</td>
<td>Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks: up to 5 mev</td>
</tr>
<tr>
<td>G6008</td>
<td>Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks: 6-10 mev</td>
</tr>
<tr>
<td>G6009</td>
<td>Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks: 11-19 mev</td>
</tr>
<tr>
<td>G6010</td>
<td>Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks: 20 mev or greater</td>
</tr>
<tr>
<td>G6011</td>
<td>Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; up to 5 mev</td>
</tr>
<tr>
<td>G6012</td>
<td>Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev</td>
</tr>
<tr>
<td>G6013</td>
<td>Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev</td>
</tr>
<tr>
<td>G6014</td>
<td>Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 mev or greater</td>
</tr>
<tr>
<td>G6015</td>
<td>Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session</td>
</tr>
<tr>
<td>G6016</td>
<td>Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session</td>
</tr>
<tr>
<td>G6017</td>
<td>Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (e.g., 3D positional tracking, gating, 3D surface tracking), each fraction of treatment</td>
</tr>
</tbody>
</table>
Description of Services

A course of radiation therapy is comprised of a series of distinct activities which includes consultation, treatment planning, technical preparation and special services, treatment delivery, treatment management, and follow-up care management. The radiation oncologist leads a team, which includes a medical radiation physicist, dosimetrist, radiation therapist, oncology nurses and ancillary staff, through the patient’s course of treatment. The team works together to coordinate the patient’s clinical treatment plan including consultations and evaluations, developing the appropriate dosimetry calculations and isodose plan, building treatment devices to refine treatment delivery, as needed, delivering the radiation therapy, and performing any other special services required to ensure safe and precise delivery of radiation therapy (ASTRO 2020).

External beam radiation therapy includes the following: three-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT), proton beam radiation therapy (PBRT).

Image-guided radiation therapy (IGRT) involves the use of patient images to localize and reposition the patient or delivery system prior to treatment to ensure that the therapeutic beam is correctly directed toward the target (Fontenot 2014).

Hypofractionated radiotherapy is the delivery of fewer and larger (>200 cGy) doses of radiation. Hypofractionation is defined in this guideline as external beam radiation therapy with a fraction size between 240 cGy and 340 cGy (Morgan 2018, Smith 2018).

Special treatment procedure covers additional physician effort, work, and technical resources involved during complex radiation treatment procedures e.g., brachytherapy, concurrent use of intravenous chemotherapy (except Herceptin use in breast cancer), reconstruction and analysis of previous radiation therapy plan, hyperthermia, total and hemi-body irradiation, per oral or endocavitary irradiation, and pediatric patient requiring anesthesia (ASTRO 2020, CMS 2015).

Special medical physics consultation is used when the complexity of the treatment plan is of such magnitude that a written analysis is necessary to address a specific problem and when the service performed requires the expertise of qualified medical physicist e.g., brachytherapy, use of radioisotopes, patient has an implanted pacemaker or defibrillator device, reconstruction of previous radiation therapy plan, pregnant patient undergoing radiation therapy or fusion of three-dimensional image sets such as PET scan or MRI scan (not separately reportable with IMRT planning code 77301) (ASTRO 2020, CMS 2015).

Clinical Evidence

Bone Metastases

Huisman et al. (2018) conducted a systematic review and meta-analysis to quantify the effectiveness of reirradiation to achieve pain control in patients with painful bone metastases. A search was performed to identify eligible studies using the MEDLINE, EMBASE, and the Cochrane Collaboration library electronic databases. Studies that met the following criteria were eligible: a portion of the participants received reirradiation at the site of initial RT for radiation-refractory metastatic bone pain; both the initial treatment and the retreatment consisted of localized EBRT; reported outcomes included (at least) pain response after reirradiation; and original research data were reported. The search identified 707 titles, of which 10 articles were selected for the systematic review and 7 were included in the meta-analysis (three articles were excluded because results could not be extracted on a per-patient level, the sample size was considered too small, or all patients received second reirradiation). Of the 10 studies, 6 were randomized trials, 2 were cohort studies, and 2 were case series. A pooled estimate was calculated for overall pain response after reirradiation for metastatic bone pain. A total of 2,694 patients were initially treated for metastatic bone pain, 527 (20%) patients underwent reirradiation. With reirradiation, the number of fractions administered ranged from a single fraction to 13 fractions. Overall, a pain response after reirradiation was achieved in 58% of patients (pooled overall response rate 0.58, 95% CI 0.49 to 0.67). There was a significant between-study heterogeneity ($I^2 = 63.3\%$, $p=0.01$) because of the clinical and methodological differences between the studies. The authors concluded that reirradiation of radiation-refractory bone pain is effective, but approximately 40% of patients do not seem to benefit from reirradiation, and more research is needed to provide optimal palliative care.

Chow et al. (2014) conducted a multi-center, non-blinded, randomized, controlled trial to assess two dose fractionation schedules in patients with painful bone metastases needing repeat radiation therapy. Patients 18 years or older who had radiologically confirmed, painful (i.e., pain measured as ≥2 points using the Brief Pain Inventory) bone metastases, had received
previous radiation therapy, and were taking a stable dose and schedule of pain-relieving drugs (if prescribed). Patients were randomly assigned (1:1) to receive either 8 Gy in a single fraction or 20 Gy in multiple fractions. The primary endpoint was overall pain response at 2 months, which was defined as the sum of complete and partial pain responses to treatment, assessed using both Brief Pain Inventory scores and changes in analgesic consumption. A total of 425 patients were enrolled however, 19 (4%) patients in the 8 Gy group and 12 (3%) in the 20 Gy group were found to be ineligible after randomization, and 140 (33%) and 132 (31%) patients, respectively, were not assessable at 2 months and were counted as missing data in the intention-to-treat analysis (ITT). The ITT population comprised 118 (28%) patients allocated to 8 Gy treatment and 135 (32%) allocated to 20 Gy treatment who had an overall pain response to treatment (p=0.21; response difference of 4.00% [upper limit of the 95% CI 9.2, less than the prespecified non-inferiority margin of 10%]). In the per-protocol population, 116 (45%) patients and 134 (51%) patients, respectively, had an overall pain response to treatment (p=0.17; response difference 6.00% [upper limit of the 95% CI 13.2, greater than the prespecified non-inferiority margin of 10%]). The most frequently reported acute radiation-related toxicities at 14 days were lack of appetite (201 [56%] assessable patients who received 8 Gy vs. 229 [66%] assessable patients who received 20 Gy; p=0.011) and diarrhea (81 [23%] patients vs. 108 [31%] patients; p=0.018). Pathological fractures occurred in 30 (7%) patients assigned to 8 Gy and 20 (5%) patients assigned to 20 Gy (Odds Ratio [OR] 1.54, 95% CI 0.85–2.75; p=0.15), and spinal cord or cauda equina compressions were reported in seven (2%) patients versus two (<1%) patients, respectively (OR 3.54, 95% CI 0.73–17.15; p=0.094). The authors concluded that in patients with painful bone metastases requiring repeat radiation therapy, treatment with 8 Gy in a single fraction seems to be non-inferior and less toxic than 20 Gy in multiple fractions; however, as findings were not robust in a per-protocol analysis, trade-offs between efficacy and toxicity may exist.

Hartsell et al. (2005) conducted multi-center, phase III, randomized trial to investigate whether 8 Gy delivered in a single treatment fraction provides pain and narcotic relief that is equivalent to that of the standard treatment course of 30 Gy delivered in 10 treatment fractions over 2 weeks. Patients with breast or prostate cancer who had one to three sites of painful bone metastases and moderate to severe pain were eligible for participation. Patients were randomly assigned to 8 Gy in one treatment fraction (8 Gy arm) or to 30 Gy in 10 treatment fractions (30 Gy arm). Pain relief at 3 months after randomization was evaluated with the Brief Pain Inventory. A total of 455 patients were allocated to the 8 Gy arm and 443 patients to the 30 Gy arm; pretreatment characteristics were equally balanced between arms. Grade 2–4 acute toxicity was more frequent in the 30 Gy arm (17%) than in the 8 Gy arm (10%) (difference = 7%, 95% CI = 3% to 12%; p=0.002). Late toxicity was rare (4%) in both arms. The overall response rate was 66%. Complete and partial response rates were 15% and 50%, respectively, in the 8 Gy arm compared with 18% and 48% in the 30 Gy arm (p=0.6). At 3 months, 33% of all patients no longer required narcotic medications. The incidence of subsequent pathologic fracture was 5% for the 8 Gy arm and 4% for the 30 Gy arm. The retreatment rate was statistically significantly higher in the 8 Gy arm (18%) than in the 30 Gy arm (9%) (p<0.001). The authors concluded that both regimens were equivalent in terms of pain and narcotic relief at 3 months and were well tolerated with few adverse effects. The 8 Gy arm had a higher rate of re-treatment but had less acute toxicity than the 30 Gy arm.

**Clinical Practice Guidelines**

**American Society for Radiation Oncology (ASTRO)**

ASTRO’s guideline on palliative radiation therapy for bone metastases states that up to 10 Gy fractions have been shown to be effective for the treatment of pain and/or prevention of morbidity from peripheral bone metastases (Lutz, 2017).

**American College of Radiology (ACR)**

ACR’s special report, Appropriateness Criteria Spinal Bone Metastases, states that randomized trials have proven that equivalent pain relief can be achieved with varied fractionation schemes including a single 8 Gy fraction, 20 Gy in 5 fractions, 24 Gy in 6 fractions, or 30 Gy in 10 fractions (Lo, 2013).

**Breast Adenocarcinoma**

Patel et al. (2019) conducted a retrospective case series analysis to evaluate acute radiation dermatitis rates with HF-WBI in large-breasted patients. Patients with whole-breast clinical target volumes (WB-CTV) of ≥1000 cm³ treated with HF-WBI were reviewed. WB-CTV V105, V107, and V110 were assessed. The investigators’ cancer center network utilizes guidelines that recommend limiting V105 to <10% to 15% and V110 to 0%. The highest grade of acute dermatitis was recorded. Potential clinical and dosimetric predictors of dermatitis were analyzed using logistic regression. A total of 505 breasts in 502 patients were treated with HF-WBI. The median WB-CTV was 1,261.3 cm³ (interquartile range [IQR], 1,115.3 to 1,510.0). Most plans (99%) delivered 42.56 Gy in 16 fractions. A cavity boost of 10 Gy in 4 fractions was delivered in 99% of plans. Electrons were
used in 69% of boost plans. Three-dimensional field-in-field technique was used in 68% of plans and inverse-planned intensity modulated radiation therapy in 32%. The median WB-CTV V105 was 9.7% (IQR, 5.6% to 13.3%); the median WB-CTV V107 was 0.8% (IQR, 0.0% to 2.5%). The WB-CTV V110 was 0% in 97.4% of plans (median, 0.0%; IQR, 0.0% to 0.0%). Grade 1, 2, and 3 dermatitis rates were 55.0%, 40.8%, and 3.4%, respectively. On multivariate analysis, age >64 years (p=0.016; OR 4.0; 95% CI, 1.3 to 12.3), WB-CTV >1500 cm³ (p=0.006; OR 4.3; 95% CI, 1.5 to 12.3), body mass index ≥34 (p=0.044; OR 3.9; 95% CI, 1.0 to 14.5), and WB-CTV V105 >10% (p=0.011; OR 5.3; 95% CI, 1.5 to 19.3) predicted for grade 3 dermatitis. The investigators concluded that with their dosimetric guidelines, grade 3 dermatitis rates with HF-WBI in large-breasted women was <5% and that WB-CTV V105 should be optimized to <10% to keep grade 3 dermatitis rates <2%.

Shaitelman et al. (2015) conducted multi-center, unblinded, randomized trial to assess acute and six-month toxicity and quality of life (QoL) with conventionally fractionated WBI (CF-WBI) versus HF-WBI. Women eligible for enrollment were age ≥ 40 years with pathologically-confirmed female carcinoma in situ (DCIS) or invasive breast cancer, stage Tis-T2, N0-N1a, M0, treated with breast conserving surgery with final negative margins (defined as no tumor on ink), with the physician-declared intent to deliver WBI without addition of a third field to cover the regional lymph nodes. Patients were randomized to treatment with either HF-WBI (42.56 Gy in 16 fractions WBI) or CF-WBI (50 Gy in 25 fractions WBI). The tumor bed boost if final margins were negative by ≥2mm or if there was a negative re-excision was 10 Gy in 4 fractions or 12.5 Gy in 5 fractions for HF-WBI and CF-WBI, respectively, and 12.5 Gy in 5 fractions or 14 Gy in 7 fractions if final margins were <2mm for HF-WBI and CF-WBI, respectively. Outcomes of interest included physician-reported acute and six-month toxicities using National Cancer Institute Common Toxicity Criteria (NCICTC) v4.0 and patient-reported QoL using the Functional Assessment of Cancer Therapy – Breast (FACT-B) version 4. A total of 287 patients were randomized and evaluable. Of 149 patients randomized to CF-WBI, all (100%) received the allocated WBI and boost doses. Of 138 patients randomized to HF-WBI, 137 (99%) received a hypofractionated schedule of WBI (n=134, 42.56 Gy/16 fractions; n=2, 42.4 Gy/16 fractions; n=1, 42.52 Gy/16 fractions) and 136 (99%) received the allocated boost dose. One (1%) patient randomized to HF-WBI received conventional fractionation (46 Gy in 23 fractions followed by a 14 Gy in 7 fraction boost). Median number of elapsed days over which radiation was delivered was 36 days for CF-WBI (IQR 35–36) and 22 days for HF-WBI (IQR 22–23). Half of the treatment plans (143) involved a Dmax of 107% of prescription dose or higher. Treatment arms were well-matched for baseline characteristics including FACT-B total score (p=0.46) and individual QoL items such as lack of energy (p=0.86) and trouble meeting family needs (p=0.54). Maximal physician-reported acute dermatitis (p<0.001), pruritus (p<0.001), breast pain (p=0.001), hyperpigmentation (p=0.002), and fatigue (p=0.02) during radiation were lower in patients randomized to HF-WBI. Overall grade ≥2 acute toxicity was less with HF-WBI vs. CF-WBI (47% vs. 78%; p<0.001). Six months after radiation, physicians reported less fatigue in patients randomized to HF-WBI (p=0.01), and patients randomized to HF-WBI reported less lack of energy (p<0.001) and less trouble meeting family needs (p=0.01). Multivariable regression confirmed the superiority of HF-WBI in terms of patient-reported lack of energy (OR 0.39, 95% CI 0.24 to 0.63) and trouble meeting family needs (OR 0.34, 95% CI 0.16 to 0.75). The authors concluded that HF-WBI appears to yield less acute toxicity than CF-WBI, as well as less fatigue and trouble meeting family needs six months after completing radiation, and that these findings should be communicated to patients as part of shared decision-making.

Haviland et al. (2013) conducted a prespecified analysis as a 10-year update to the UK Standardisation of Breast Radiotherapy (START) trials (ISRCTN59368779). The START trials (START-A and START-B) were multi-center, randomized, unmasked trials. Patients were recruited after complete excision of primary invasive breast cancer (pT1–3a, pN0–1, M0) and referred for radiotherapy as part of standard treatment. Patients in START-A (n=2,236) were randomly assigned to either 50 Gy in 25 fractions (control group) or 41.6 Gy in 13 fractions or 39 Gy in 13 fractions over 5 weeks, and START-B patients (n=2,215) to either 50 Gy in 25 fractions (control group) over 5 weeks or 40 Gy in 15 fractions over 3 weeks. Five-year results suggested that lower total doses of radiotherapy delivered in fewer, larger doses (fractions) are at least as safe and effective as the historical standard regimen (50 Gy in 25 fractions) for women after primary surgery for early breast cancer. In this follow-up analysis, patients in START-A had a median follow-up of 9.3 years (IQR 8.0 to 10.0), after which 139 local-regional relapses had occurred. Ten-year rates of local-regional relapse did not differ significantly between the 41.6 Gy and 50 Gy regimen groups (6.3%, 95% CI 4.7 to 8.5 vs. 7.4%, 5.5 to 10.0; Hazard Ratio [HR] 0.91, 95% CI 0.59 to 1.38; p=0.65) or the 39 Gy (8.8%, 95% CI 6.7 to 11.4) and 50 Gy regimen groups (HR 1.18, 95% CI 0.79 to 1.76; p=0.41). In START-A, moderate or marked breast induration, telangiectasia, and breast edema were significantly less common normal tissue effects in the 39 Gy group than in the 50 Gy group. Normal tissue effects did not differ significantly between 41.6 Gy and 50 Gy groups. Patients in START-B had a median follow-up of 9.9 years (IQR 7.5 to 10.1), after which 95 local-regional relapses had occurred. The proportion of patients with local-regional relapse at 10 years did not differ significantly between the 40 Gy group (4.3%, 95% CI 3.2 to 5.9) and the 50 Gy group (5.5%, 95% CI 4.2 to 7.2; HR 0.77, 95% CI 0.51 to 1.16; p=0.21). In START-B, breast shrinkage, telangiectasia, and breast edema were significantly less common normal tissue effects in the 40 Gy group than in the 50 Gy group. The authors
concluded that long-term follow-up confirms that appropriately dosed hypofractionated radiotherapy is safe and effective for patients with early breast cancer, and that their results support the continued use of 40 Gy in 15 fractions.

Whelan et al. (2010) conducted a multi-center, randomized trial to determine whether a hypofractionated 3-week schedule of whole-breast irradiation is as effective as a 5-week schedule. Women with invasive breast cancer who had undergone breast-conserving surgery and in whom resection margins were clear and axillary lymph nodes were negative were randomly assigned to receive whole-breast irradiation either at a standard dose of 50.0 Gy in 25 fractions over a period of 35 days (the control group) or at a dose of 42.5 Gy in 16 fractions over a period of 22 days (the hypofractionated-radiation group). After completion of radiation therapy, patients were seen every 6 months for 5 years and then yearly. The primary outcome was any local recurrence of invasive cancer in the treated breast. Secondary outcomes were a distant (including regional) recurrence of breast cancer; second cancers, including contralateral breast cancer; breast cosmesis; late toxic effects of radiation; and death. A total of 1,234 patients underwent randomization, with 612 assigned to the control group and 622 to the hypofractionated-radiation group. The two groups were similar at baseline. The risk of local recurrence at 10 years was 6.7% among the 612 women assigned to standard irradiation as compared with 6.2% among the 622 women assigned to the hypofractionated regimen (absolute difference, 0.5 percentage points; 95% CI, −2.5 to 3.5). At 10 years, 71.3% of women in the control group as compared with 69.8% of the women in the hypofractionated-radiation group had a good or excellent cosmetic outcome (absolute difference, 1.5 percentage points: 95% CI, −6.9 to 9.8). The authors concluded that ten years after treatment, accelerated, hypofractionated whole-breast irradiation was not inferior to standard radiation treatment in women who had undergone breast-conserving surgery for invasive breast cancer with clear surgical margins and negative axillary nodes.

Clinical Practice Guidelines

American Society for Radiation Oncology (ASTRO)

ASTRO's guideline on radiation therapy for the whole breast states that for women with invasive breast cancer receiving WBI with or without inclusion of the low axilla, the preferred dose-fractionation scheme is hypofractionated-WBI to a dose of 4000 Gy in 15 fractions or 4250 Gy in 16 fractions. The guideline also states that in the presence of strong risk factors for local recurrence, e.g., the single risk factor of positive margins or a combination of risk factors such as young age and close margins, a boost dose of 1250 Gy in 5 fractions or 1400 to 1600 Gy in 7 to 8 fractions may be used (Smith 2018).

Locally Advanced Non-Small Cell Lung Cancer

Bradley et al. (2015) conducted a multi-center, open-label randomized trial to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to concurrent chemoradiation for patients with inoperable stage III non-small-cell lung cancer. Patients (aged ≥ 18 years) with unresectable stage III non-small-cell lung cancer, a Zubrod performance status of 0-1, adequate pulmonary function, and no evidence of supraclavicular or contralateral hilar adenopathy were randomly assigned to receive either 60 Gy (standard dose), 74 Gy (high dose), 60 Gy plus cetuximab, or 74 Gy plus cetuximab. All patients also received concurrent chemotherapy with 45 mg/m² paclitaxel and carboplatin once a week; 2 weeks after chemoradiation, two cycles of consolidation chemotherapy separated by 3 weeks were given consisting of paclitaxel (200 mg/m²) and carboplatin. The radiation dose was prescribed to the planning target volume and was given in 2 Gy daily fractions with either intensity-modulated radiation therapy or three-dimensional conformal radiation therapy. The coprimary objectives were to compare the OS of patients given 74 Gy with those given 60 Gy conformal radiation therapy with concurrent chemotherapy and to compare the OS of patients given cetuximab with those not given cetuximab. There were several secondary objectives including a comparison of progression-free survival and local regional tumor control, comparison of toxic effects between 74 Gy versus 60 Gy, and between cetuximab versus without cetuximab, to assess patient-reported quality of life in each group of the trial and to explore biological markers that might predict clinical outcome. One hundred and sixty-six patients were randomly assigned to receive standard-dose chemoradiotherapy, 121 to high-dose chemoradiotherapy, 147 to standard-dose chemoradiotherapy and cetuximab, and 110 to high-dose chemoradiotherapy and cetuximab. Median follow-up for the radiotherapy comparison was 22.9 months (IQR 27.5 to 33.3). Median overall survival was 28.7 months (95% CI 24.1 to 36.9) for patients who received standard-dose radiotherapy and 20.3 months (17.7 to 25.0) for those who received high-dose radiotherapy (HR 1.38, 95% CI 1.09 to 1.76; p=0.004). Median follow-up for the cetuximab comparison was 21.3 months (IQR 23.5 to 29.8). Median overall survival in patients who received cetuximab was 25.0 months (95% CI 20.2 to 30.5) compared with 24.0 months (19.8 to 28.6) in those who did not (HR 1.07, 95% CI 0.84 to 1.35; p=0.29). Both the radiation-dose and cetuximab results crossed protocol-specified futility boundaries. There were no statistical differences in grade 3 or worse toxic effects between radiotherapy groups. By contrast, the use of cetuximab was associated with a higher rate of grade 3 or worse toxic effects (205 [86%] of 237 vs. 160 [70%] of 228 patients; p<0.0001). There were more treatment-related deaths in the high-dose chemoradiotherapy and cetuximab groups (radiotherapy
result of prostate cancer occurred in the short arm and 12 in the standard arm. No significant differences were detected

Lee et al. (2016) conducted a multi-center, randomized noninferiority trial to assess whether the efficacy of a HFRT treatment

authors state that hypofractionated RT is more convenient for patients and should be considered for intermediate-risk prostate

used in this trial was not inferior to conventional RT and was not associated with increased late toxicity. Furthermore, that

between arms for grade ≥ 3 late genitourinary and GI toxicity. The authors concluded that the hypofractionated RT regimen

were PSA failures. The 5-year BCF disease-free survival was 85% in both arms (HR 0.96; 90% CI, 0.77 to 1.2). Ten deaths as a


fractionation for curative intent chemoradiation therapy is 60 Gy given in 2 Gy once daily fractions over 6 weeks (Rodrigues

Catton et al. (2017) conducted a multi-center, randomized noninferiority trial to determine whether hypofractionation versus

Prostate Adenocarcinoma

Catton et al. (2017) conducted a multi-center, randomized noninferiority trial to determine whether hypofractionation versus

conventional fractionation is similar in efficacy without increased toxicity. Patients with intermediate-risk prostate cancer (T1 to

2a, Gleason score ≤ 6, and prostate-specific antigen [PSA] 10.1 to 20 ng/mL; T2b to 2c, Gleason ≤ 6, and PSA ≤ 20 ng/mL; or

T1 to 2, Gleason = 7, and PSA ≤ 20 ng/mL) were eligible to participate. Patients were randomized to conventional RT of 78 Gy

in 39 fractions over 8 weeks or to hypofractionated RT of 60 Gy in 20 fractions over 4 weeks. Androgen deprivation was not

permitted with therapy. The primary outcome was biochemical-clinical failure (BCF) defined by any of the following: PSA failure

(nadir + 2), hormonal intervention, clinical local or distant failure, or death as a result of prostate cancer. The noninferiority

margin was 7.5% (HR < 1.32). A total of 1,206 patients were randomized, with 608 patients allocated to the hypofractionated RT

group (short arm) and 598 patients to the control RT group (standard arm). Median follow-up was 6.0 years. Most of the events

were PSA failures. The 5-year BCF disease-free survival was 85% in both arms (HR 0.96; 90% CI, 0.77 to 1.2). Ten deaths as a

result of prostate cancer occurred in the short arm and 12 in the standard arm. No significant differences were detected

between arms for grade ≥ 3 late genitourinary and GI toxicity. The authors concluded that the hypofractionated RT regimen

used in this trial was not inferior to conventional RT and was not associated with increased late toxicity. Furthermore, that

authors state that hypofractionated RT is more convenient for patients and should be considered for intermediate-risk prostate

cancer.

Lee et al. (2016) conducted a multi-center, randomized noninferiority trial to assess whether the efficacy of a HFRT treatment

schedule is no worse than a conventional radiotherapy (C-RT) schedule in men with low-risk prostate cancer. Men age > 18

years with prostate adenocarcinoma were eligible if they met the following criteria: a clinical classification of T1b to T2c

(according to American Joint Committee on Cancer staging system, 6th edition), a Gleason score of 2 to 6, and a prostate-
specific antigen (PSA) < 10. Additional criteria were no nodal or distant metastatic disease, Zubrod performance status < 2, and

no prior bilateral orchiectomy, chemotherapy, RT, cryosurgery, or definitive surgery for prostate cancer. RT was initiated within

6 weeks of registration, using either 3D-CRT or IMRT. Participants were assigned either to 73.8 Gy in 41 fractions over 8.2

weeks (C-RT) or to 70 Gy in 28 fractions over 5.6 weeks (HFRT). The primary study end point was disease-free survival (DFS),

which included local progression, distant metastatic progression, biochemical recurrence as defined by the RTOG Phoenix

definition, or death from any cause. Additional end points were OS, prostate cancer–specific survival, time to local progression,

and time to biochemical recurrence. A total of 1,092 men were protocol eligible and had follow-up information; 542 patients

were assigned to C-RT and 550 to HFRT. The median follow-up was 5.8 years. Baseline characteristics did not differ between

the treatment groups. The estimated 5-year DFS was 85.3% (95% CI, 81.9 to 88.1) in the C-RT arm and 86.3% (95% CI, 83.1 to

89.0) in the HFRT arm. The DFS HR was 0.85 (95% CI, 0.64 to 1.14), and the predefined noninferiority criterion that required

that DFS outcomes be consistent with HR < 1.52 was met (p<0.001). Late grade 2 and 3 gastrointestinal (GI) and genitourinary

(GU) adverse events were increased (HR 1.31 to 1.59) in patients who were treated with HFRT. The authors concluded that in

men with low-risk prostate cancer, efficacy of 70 Gy in 28 fractions over 5.6 weeks is not inferior to 73.8 Gy in 41 fractions over

8.2 weeks, although an increase in late GI/GU adverse events was observed in patients treated with HFRT.

The Hypofractionated Irradiation for Prostate Cancer (HYPRO) trial was a multi-center, open label, randomized trial to

investigate whether hypofractionated external beam radiotherapy improves relapse-free survival without increasing toxic effects,

compared with conventionally fractionated radiotherapy. Patients at intermediate- risk or high-risk, between 44 and 85 years of

age with histologically confirmed stage T1b–T4 NX-OMX-0 prostate cancer, a prostate-specific antigen concentration of 60
ng/mL or lower, and a WHO performance status of 0–2 were eligible to participate. Enrolled participants were randomly assigned to receive either standard fractionation with 39 fractions of 2 Gy in 8 weeks (five fractions per week) or hypofractionation with 19 fractions of 3.4 Gy in 6.5 weeks (three fractions per week). The primary endpoint was 5-year relapse-free survival and secondary outcomes included acute and late genitourinary and gastrointestinal toxicity. Non-inferiority of hypofractionation was tested separately for genitourinary and gastrointestinal acute toxic effects, with a null hypothesis that cumulative incidences of each type of adverse event were not more than 8% higher in the hypofractionation group than in the standard fractionation group. In 2015, Aluwin et al., reported results for a total of 820 participants in the HYPRO study who were randomly assigned to treatment with standard fractionation (n=410) or hypofractionation (n=410). The authors concluded that hypofractionated radiotherapy was not non-inferior to standard fractionated radiotherapy in terms of acute genitourinary and gastrointestinal toxicity for men with intermediate-risk and high-risk prostate cancer, and the cumulative incidence of grade 2 or worse acute gastrointestinal toxicity was significantly higher in patients given hypofractionation than in those given standard fractionated radiotherapy. However, the authors also stated that before final conclusions can be made about the utility of hypofractionation, efficacy outcomes were needed. In 2016 Incrocci et al., reported 5-year relapse-free survival outcomes. Relapse-free survival at 5 years was 80.5% (95% CI 75.7 to 84.4) for patients assigned hypofractionation and 77.1% (71.9 to 81.5) for those allocated conventional fractionation (adjusted HR 0.86, 95% CI 0.63 to 1.16; log-rank p=0.36). There were no treatment-related deaths. The authors concluded that based on all of the HYPRO trial evidence, hypofractionated radiotherapy (19 fractions of 3.4 Gy) was not superior to conventional radiotherapy with respect to 5-year relapse-free survival, and that their hypofractionated radiotherapy regimen cannot be regarded as the new standard of care for patients with intermediate-risk or high-risk prostate cancer.

Dearnaley et al. (2016) conducted a multi-center, randomized non-inferiority trial comparing a conventionally fractionated schedule with two experimental hypofractionated schedules in men with localized prostate cancer. Men older than 16 years who had histologically confirmed T1b–T3aN0M0 prostate cancer and a WHO performance status of 0 or 1 were eligible. Patients were randomly assigned to conventional (74 Gy delivered in 37 fractions over 7.4 weeks) or one of two hypofractionated schedules (60 Gy in 20 fractions over 4 weeks or 57 Gy in 19 fractions over 3.8 weeks) all delivered with intensity-modulated techniques. Most patients were given radiotherapy with 3 to 6 months of neoadjuvant and concurrent androgen suppression. The primary endpoint was time to biochemical or clinical failure; the critical HR for non-inferiority was 1.208. A total of 3,216 men were enrolled and randomly assigned (74 Gy group, 1,065 patients; 60 Gy group, 1,074 patients; 57 Gy group, 1,077 patients). The median follow-up was 62.4 months (IQR 53.9 to 77.0). The proportion of patients who were biochemical or clinical failure free at 5 years was 88.3% (95% CI 86.0 to 90.2) in the 74 Gy group, 90.6% (88.5 to 92.3) in the 60 Gy group, and 85.9% (83.4 to 88.0) in the 57 Gy group. Sixty Gy was non-inferior to 74 Gy (HR 0.84, 90% CI 0.68 to 1.03; p=0.0018) but non-inferiority could not be claimed for 57 Gy compared with 74 Gy (HR 1.20, 0.99 to 1.46; p=0.48). Long-term side-effects were similar in the hypofractionated groups compared with the conventional group. There were no significant differences in either the proportion or cumulative incidence of side-effects 5 years after treatment using three clinician-reported as well as patient-reported outcome measures. The estimated cumulative 5 year incidence of Radiation Therapy Oncology Group (RTOG) grade 2 or worse bowel and bladder adverse events was 13.7% (111 events) and 9.1% (66 events) in the 74 Gy group, 11.9% (105 events) and 11.7% (88 events) in the 60 Gy group, 11.3% (95 events) and 6.6% (57 events) in the 57 Gy group, respectively. No treatment-related deaths were reported. The authors concluded that hypofractionated radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fractionation using 74 Gy in 37 fractions, and is recommended as a new standard of care for external-beam radiotherapy of localized prostate cancer.

Clinical Practice Guidelines

American Society for Radiation Oncology (ASTRO)

ASTRO’s guideline on hypofractionated radiation therapy for the localized prostate cancer states that based on high-quality evidence, moderate hypofractionated external beam radiation therapy (defined as 240 to 340 Gy per fraction) should be recommended to low-risk and intermediate-risk patients who opt for active treatment, and patients with high-risk when the pelvic nodes will not be treated. Based on moderate-quality evidence the guideline conditionally recommends regimens of 6000 Gy delivered in 20 fractions of 300 Gy and 7000 Gy delivered in 28 fractions of 250 Gy. The guideline also states that men should be counseled about the small increased risk of acute gastrointestinal (GI) toxicity with moderate hypofractionation however, late GI and GU toxicities were similar in hypofractionated and conventional treatments, and that a single optimal regimen cannot yet be identified as studies with head-to-head comparisons of multiple fractionation schemes have not been completed (Morgan 2018).
IGRT

Yao et al. (2019) conducted a case series analysis to investigate the setup uncertainties and to establish an optimal imaging schedule for the prone-positioned whole breast radiotherapy. Twenty prone-positioned breast patients treated with tangential fields from 2015 to 2017 were retrospectively enrolled in this study. The prescription dose for the whole breast treatment was 266 Gy × 16 for all of the patients and the treatments were delivered with the source to surface distance (SSD) setup technique. At every fraction of treatment, the patient was set up based on the body localization tattoos. Mega-voltage (MV) portal imaging was then taken to confirm the setup; if a discrepancy (> 3 mm) was found between the portal images and corresponding plan images, the patient positioning was adjusted accordingly with couch movement. Based on the information acquired from the daily tattoo and portal imaging setup, three sets of data, named as weekly imaging guidance (WIG), no daily imaging guidance (NIG), and initial 3 days then weekly imaging guidance (3 + WIG) were sampled, constructed, and analyzed in reference to the benchmark of the daily imaging guidance (DIG). A comparison of the setup uncertainties, target coverage (D$_{95}$, D$_{max}$), V$_5$ of the ipsilateral lung, the mean dose of heart, the mean and max dose of the left-anterior-descending coronary artery (LAD) among the four imaging guidance (IG) schedules were made. Relative to the daily imaging guidance (IG) benchmark, the NIG schedule led to the largest residual setup uncertainties; the uncertainties were similar for the WIG and 3 + WIG schedules. Little variations were observed for D$_{95}$ of the target among NIG, DIG and WIG. The target D$_{max}$ also exhibited little changes among all the IG schedules. While V$_5$ of the ipsilateral lung changed very little among all 4 schedules, the percent change of the mean heart dose was more pronounced; but its absolute values were still within the tolerance. However, for the left-sided breast patients, the LAD dose could be significantly impacted by the imaging schedules and could potentially exceed its tolerance criteria in some patients if NIG, WIG and 3 + WIG schedules were used. The authors concluded that for left-side whole breast treatment in the prone position using the SSD treatment technique, the daily imaging guidance can ensure dosimetric coverage of the target as well as preventing critical organs, especially LAD, from receiving unacceptable levels of dose. For right-sided whole breast treatment in the prone position, the weekly imaging setup guidance appears to be the optimal choice.

Kilburn et al. (2016) conducted a retrospective cohort analysis to determine if treatment planning based on individualized tumor motion with four-dimensional CT imaging, followed by daily IGRT with daily kilo-voltage ConeBeam computed tomography (kV CBCT) allows more accurate tumor targeting with improved local control and reduced side effects compared to weekly two-dimensional MV portal imaging based on bony landmarks. Patients with stage IIB to IIIB NSCLC who were treated with concurrent chemotherapy and external beam radiation therapy with curative intent were included in the study. Patients in both cohorts (IGRT and non-IGRT) were treated with either three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT). Outcomes included failure-free survival (FFS) for local (LFFS), regional (RFFS), locoregional (LRFFS), distant (DFFS) disease, progression-free survival (PFS), and overall survival (OS) and were estimated using Kaplan Meier method. Univariate and multivariate models were used to assess the association between patient and treatment-related covariates and local failure. A total of 169 patients were treated with definitive radiotherapy and concurrent chemotherapy with a median follow-up of 48 months in the IGRT cohort and 96 months in the non-IGRT cohort. IGRT was utilized in 36% (62 patients) of patients. OS was similar between cohorts (2-year OS, 47% vs. 49%, p=0.63). The IGRT cohort had improved two-year LFFS (80% vs. 64%, p=0.013) and LRFFS (75% and 62%, p=0.04). Univariate analysis revealed that IGRT and treatment year improved LFFS while group stage, dose, and PET/CT planning had no impact. IGRT remained significant in the multivariate model with an adjusted HR of 0.40 (p=0.01). DFFS (58% vs. 59%, p=0.67) did not differ significantly. The authors concluded that IGRT with daily CBCT confers an improvement in the therapeutic ratio compared with patients treated without IGRT.

Nabavizadeh et al. (2016) conducted a conducted a survey of the American Society for Radiation Oncology (ASTRO) physician membership to identify IGRT practice patterns, as well as IGRT’s impact on clinical workflow and planning treatment volumes (PTVs). A sample of 5,979 treatment site–specific surveys was emailed to the membership of the American Society for Radiation Oncology (ASTRO), with questions pertaining to IGRT modality/frequency, PTV expansions, method of image verification, and perceived utility/value of IGRT. On-line image verification was defined as images obtained and reviewed by the physician before treatment. Off-line image verification was defined as images obtained before treatment and then, reviewed by the physician before the next treatment. Of 601 evaluable responses, 95% reported IGRT capabilities other than portal imaging. The majority (92%) used volumetric imaging (CBCT or megavoltage computed tomography [MVCT]), with volumetric imaging being the most commonly used modality for all sites except breast. The majority of respondents obtained daily CBCTs for head and neck intensity modulated radiation therapy (IMRT), lung 3-dimensional conformal radiation therapy or IMRT, anus or pelvis IMRT, prostate IMRT, and prostatic fossa IMRT. For all sites, on-line image verification was most frequently performed during the first few fractions only. No association was seen between IGRT frequency or CBCT utilization and clinical treatment volume to PTV expansions. Of the 208 academic radiation oncologists who reported working with residents, only 41% reported trainee involvement in IGRT verification processes. The authors concluded that consensus guidelines, further evidence-based approaches for PTV margin selection, and greater resident involvement are needed for standardized use of IGRT practices.
Korreman et al. (2012) conducted a multi-center case series analysis to quantify the effects of four-dimensional computed tomography (4DCT), 4D image guidance (4D-IG), and beam gating on calculated treatment field margins in a lung cancer patient population. A total of 46 patients with non-small-cell lung cancer participated in four separate motion management protocols. Respiration-correlated imaging was performed for treatment planning purposes for all patients; 9 patients were imaged with 4DCT scans, 7 patients were imaged using fluoroscopy (with gold seeds in tumors), and 30 patients were imaged using 4DCT (5 patients had an implanted fiducial marker). The magnitude of respiratory tumor motion was measured. The required treatment field margins were calculated using a statistical recipe (van Herk 2000), with magnitudes of all uncertainties, except respiratory peak-to-peak displacement, the same for all patients. Required margins for respiratory motion management were calculated using the residual respiratory tumor motion for each patient for various motion management strategies. Margin reductions for respiration management were calculated using 4DCT, 4D-IG, and gated beam delivery. The median tumor motion magnitude was 4.4 mm for the 46 patients (range, 0 to 29.3 mm). This value corresponded to required treatment field margins of 13.7 to 36.3 mm (median 14.4 mm). The use of 4DCT, 4D-IG, and beam gating required margins that were reduced by 0 to 13.9 mm (median 0.5 mm), 3 to 5.2 mm (median 5.1 mm), and 0 to 7 mm (median 0.2 mm), respectively, to a total of 8.5 to 12.4 mm (median 8.6 mm). The authors concluded that a respiratory management strategy for lung cancer radiotherapy including planning on 4DCT scans and daily image guidance provides a potential reduction of 37% to 47% in treatment field margins and therefore, the 4D image guidance strategy was the most effective strategy for >85% of the patients in their study.

Lin et al. (2012) conducted a single-center retrospective case series analysis to determine the impact of body mass index (BMI) on daily setup variations and frequency of imaging necessary for patients with endometrial cancer treated with adjuvant IMRT with daily image guidance. BMI, mean daily shifts, and random and systematic errors in each translational and rotational direction were calculated for each patient. Margin recipes were generated based on BMI. Linear regression and spearman rank correlation analysis were performed. To simulate a less-than-daily IGRT protocol, the average shift of the first five fractions was applied to subsequent setups without IGRT for assessing the impact on setup error and margin requirements. A total of 30 patients were included in the analysis. All patients underwent surgery for endometrial cancer, including a total hysterectomy, bilateral salpingo-oophorectomy, and pelvic/para-aortic lymph node dissection for endometrial cancer. Stages ranged from IB to IIIC. Of the patients, 6 had uterine sarcoma, 21 had endometrioid adenocarcinoma, and 3 had papillary serous carcinoma. One patient received pelvic radiation for a recurrence of endometrial cancer. The median patient age was 59 years (range, 45 to 82 years). The median BMI was 32.9 (range, 23 to 62). Of the 30 patients, 16.7% (n=5) were normal weight (BMI <25); 23.3% (n=7) were overweight (BMI ≥25 to <30); 26.7% (n=8) were mildly obese (BMI ≥30 to <35); and 33.3% (n=10) were moderately to severely obese (BMI ≥35). On linear regression, mean absolute vertical, longitudinal, and lateral shifts positively correlated with BMI (p=0.0127, p=0.0037, and p <0.0001, respectively). Systematic errors in the longitudinal and vertical direction were found to be positively correlated with BMI category (p<0.0001 for both). IGRT for the first five fractions, followed by correction of the mean error for all subsequent fractions, led to a substantial reduction in setup error and resultant margin requirement overall compared with no IGRT. The authors concluded that daily shifts, systematic errors, and margin requirements were highest in patients who were obese and as such, tailored use of image-guided IMRT in women with a high BMI receiving pelvic radiotherapy, is thus appropriate.

Chen et al. (2007) conducted a retrospective case series analysis to determine the optimal definition of target margins for patients with esophageal carcinoma and treated with conformal RT. Pretreatment megavoltage computed tomography (MVCT) scans were used to evaluate setup variations in anterior-posterior (AP), lateral, and superior-inferior (SI) directions and rotational variations, including pitch, roll, and yaw, for patients with pathologically confirmed esophageal carcinoma and treated with helical tomotherapy. A total of 10 patients were included in the analysis; 8 had adenocarcinoma, and 2 had squamous cell carcinoma. After patients were positioned using their skin tattoos/marks, megavoltage computed tomography (MVCT) scans were performed before every treatment and automatically registered to planning kilovoltage CT scans according to bony landmarks. Image registration data were used to adjust patient setups before treatment. A total of 250 MVCT scans were analyzed. Correlations between setup variations and body habitus, including height, weight, relative weight change, body surface area, and patient age, were evaluated. The standard deviations for systematic setup corrections in AP, lateral, and SI directions and pitch, roll, and yaw rotations were 1.5, 3.7, and 4.8 mm and 0.5°, 1.2°, and 0.8°, respectively. The appropriate averages of random setup variations in AP, lateral, and SI directions and pitch, roll, and yaw rotations were 2.9, 5.2, and 4.4 mm, and 1.0°, 1.2°, and 1.1°, respectively. Setup variations were stable throughout the entire course of radiotherapy in all three translational and three rotational displacements, with little change in magnitude. No significant correlations were found between setup variations and body habitus variables. The authors concluded that daily MVCT scans before each treatment can effectively detect setup errors and thus reduce planning target volume (PTV) margins. This will reduce radiation dose to critical organs and may lower treatment-related toxicities.
Kotte et al. (2007) conducted a case series analysis to evaluate the intrafraction motion of the prostate during external-beam radiation therapy of patients with prostate cancer. A total of 427 patients with Stage T3Nx/0Mx/0 prostate carcinoma who received IMRT treatment combined with position verification with fiducial gold markers were included in the analysis. For a total of 11,426 treatment fractions (average, 27 per patient), portal images were taken of the first segment of all five beams. The irradiation time of the technique varied between 5–7 min. From these data, the location of gold markers could be established within every treatment beam under the assumption of minimal marker movement. In 66% of treatment fractions, a motion outside a range of 2 mm was observed, with 28% outside a range of 3 mm. The intrafraction marker movements showed that motion directions were often reversed. However, the effect was small. Even with perfect online position-correction at the start of irradiation, intrafraction motion caused position uncertainty, but systematic errors (∑) were limited to <0.6 mm, and random errors (σ) to <0.9 mm. This would result in a lower limit of 2 mm for margins, in the absence of any other uncertainties. The authors concluded that intrafraction motion of the prostate occurs frequently during external-beam irradiation on a time scale of 5–7 min. Margins of 2 mm account for these intrafraction motions. However, larger margins are required in practice to accommodate other uncertainties in the treatment.

The NCCN guideline for prostate cancer states that a conventional fractionation regimen consists of 1.8 to 2.0 Gy in 37 to 45 fractions (2020).

**Clinical Practice Guidelines**

**American Association of Physicists in Medicine (AAPM)**

AAPM’s report, Quality Assurance for Image-Guided Radiation Therapy utilizing CT-based Technologies, states that CT-based image-guidance systems have the potential to profoundly change how radiation therapy is delivered. Quality control protocols used for these devices are highly dependent on their intended use. The primary aim of image-guidance is to detect and correct positional uncertainties and as such, attention should be given to the geometric accuracy assessment. As PTV margins become tighter, the geometric accuracy of radiation therapy delivery systems becomes as important as the dosimetric accuracy, meriting implementation of daily quality control procedures (Bissonnette, 2012).

**American College of Radiology (ACR)**

ACR’s Practice Parameter for Image-Guided Radiation Therapy states IGRT has led to substantially greater accuracy and precision of radiation delivery. The need for accuracy and precision has been increased by research, which shows that the accuracy of targeting using IGRT significantly affects overall survival. This need for accuracy is potentially being met by ongoing advances in radiation planning and delivery that allow for much more conformal dose distributions, sharper dose gradients, and higher doses per fraction. Thus, IGRT is particularly applicable to highly conformal treatment modalities, such as 3-D conformal radiation therapy (CRT), intensity-modulated radiation therapy (IMRT), or heavy particle therapy. Common indications for IGRT include any target volume located near or within critical structures and/or in tissue with inherent setup variation, any target volume in close proximity to critical structures that must be protected, any volume of interest that is subject to daily variation that is due to internal motion, any target where the adjacent area has been previously irradiated and abutting fields must be precise, or any scenario in which dose escalation is planned beyond the usual doses for similar tumors (2019).

**American Society for Radiation Oncology (ASTRO)**

ASTRO’s white paper on safety considerations for IGRT states that it is a powerful tool that enables radiation oncologists to further increase the conformity of radiation delivery, with higher dose prescriptions and shorter fractionation schedules. However, IGRT is time and resource intensive and increases the need for process-oriented thinking and inter-professional communication. The white paper recommends that practitioners work together as a team to address environmental and technical concerns, documented standard operating procedures should be followed for planning to ensure PTVs are properly constructed, and that team members allow adequate time for quality assurance checks and to investigate any problems (Jaffray, 2013).

**U.S. Food and Drug Administration (FDA)**

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.
Radiation therapy is a procedure and, therefore, is not subject to FDA regulation. However, the FDA has approved the accelerators and other equipment used to generate and deliver PBRT. See the following website for more information (use product code LHN): http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm. (Accessed July 30, 2020)

The FDA has approved a number of devices for use in IMRT, SBRT and SRS. See the following website for more information (use product codes MUJ and IYE): http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm. (Accessed July 30, 2020)

References


Policy History/Revision Information

<table>
<thead>
<tr>
<th>Date</th>
<th>Summary of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/01/2021</td>
<td>• New Medical Policy</td>
</tr>
</tbody>
</table>

Proprietary Information of UnitedHealthcare. Copyright 2021 United HealthCare Services, Inc.
Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.